Celyad SA (CYAD): Price and Financial Metrics
GET POWR RATINGS... FREE!
CYAD POWR Grades
- Growth is the dimension where CYAD ranks best; there it ranks ahead of 0% of US stocks.
- 500 - Internal server error
- CYAD ranks lowest in Growth; there it ranks in the 0th percentile.
CYAD Stock Summary
- Celyad Oncology SA's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 8.09% of US listed stocks.
- CYAD's price/sales ratio is 13,416.13; that's higher than the P/S ratio of 99.82% of US stocks.
- Revenue growth over the past 12 months for Celyad Oncology SA comes in at -99.83%, a number that bests only 0.5% of the US stocks we're tracking.
- Stocks that are quantitatively similar to CYAD, based on their financial statements, market capitalization, and price volatility, are VNRX, INMB, SPCE, CRNX, and GENE.
- Visit CYAD's SEC page to see the company's official filings. To visit the company's web site, go to www.celyad.com.
CYAD Stock Price Chart Interactive Chart >
CYAD Price/Volume Stats
|Current price||$5.67||52-week high||$13.01|
|Prev. close||$5.66||52-week low||$5.27|
|Day high||$5.82||Avg. volume||25,056|
|50-day MA||$7.00||Dividend yield||N/A|
|200-day MA||$8.44||Market Cap||80.54M|
Celyad SA (CYAD) Company Bio
Celyad SA is a leader in engineered cell therapy treatments with clinical programs initially targeting indications in cardiology and oncology. The company was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.
CYAD Latest News Stream
|Loading, please wait...|
CYAD Latest Social Stream
View Full CYAD Social Stream
Latest CYAD News From Around the Web
Below are the latest news stories about Celyad Oncology SA that investors may wish to consider to help them evaluate CYAD as an investment opportunity.
MONT-SAINT-GUIBERT, Belgium, May 04, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced that Tolefi SA’s shares benefit from a double voting right as of May 3, 2021. As a result, the Company’s total number of voting rights is now 17,373,181. This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.Figures – Modified on 3 May 2021 following the Double Voting Rights: Total amount of share capital (EUR)52,211,200.33Total Number of sh...
Celyad Oncology (CYAD) appoints Dr. Charles Morris to the position of Chief Medical Officer ((CMO)). Dr. Morris is a medical oncologist with over 20 years of oncology drug development experience in international biotech and pharmaceutical space.Prior to joining Celyad, Dr. Morris served as CMO of Radius Health and held leadership...
MONT-SAINT-GUIBERT, Belgium, April 19, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced the appointment of Dr. Charles Morris to the position of Chief Medical Officer. Dr. Morris will lead and provide strategic direction for all medical, regulatory and clinical development activities. “We are delighted to bring someone with Dr. Morris’s vast expertise and experience on board during this pivotal time in the Company,” said Filippo Petti, CEO of Celyad Oncology. “Dr. Morris has played an integral part in guiding multiple late-stage oncology drugs to approval and his demonstrated track record of leadership in the ph...
NEW YORK, NY / ACCESSWIRE / March 25, 2021 / Celyad Oncology SA (NASDAQ:CYAD) will be discussing their earnings results in their 2020 Second Half Earnings call to be held on March 25, 2021 at 1:00 PM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.
No safety concerns or evidence of Graft-versus-Host disease reported from first dose cohort of Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM); enrollment in second dose cohort initiated with additional proof-of-concept data anticipated in Q2 2021Enrollment ongoing in expansion segment of Phase 1 alloSHRINK trial evaluating CYAD-101 administered concurrently with FOLFIRI preconditioning chemotherapy for the treatment of advanced metastatic colorectal cancer (mCRC); preliminary data from expansion cohort expected in Q2 2021On track to initiate Phase 1b KEYNOTE-B79 trial evaluating CYAD-101 with KEYTRUDA® in patients with microsatellite stable mCRC in the first half of 2021Patient enrollm...
CYAD Price Returns